Cordatus Wealth Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Cordatus Wealth Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$742K	Buy	8,063 +3,093	+62%	+$261K	0.28%	115
2020 Q4	$364K	Buy	+4,970	New	+$369K	0.15%	123

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Cordatus Wealth Management's HZNP Position: Q1 2021 in Review

Cordatus Wealth Management increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 62% in Q1 2021, buying an estimated $261K and bringing the position to 8,063 shares worth $742K. The position accounts for 0.28% of the portfolio, ranked #115.

Cordatus Wealth Management first reported a position in HZNP in Q4 2020 and has held it in 2 quarters since. 516 funds tracked by Wall St. Rank hold HZNP as of Q1 2021.

Cordatus Wealth Management held 8,063 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $742K as of Q1 2021.
Cordatus Wealth Management bought 3,093 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2021, an estimated $261K.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.28% of Cordatus Wealth Management's portfolio in Q1 2021, its #115 holding.
Cordatus Wealth Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and has held it in 2 quarters since.
516 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2021.

Based on Cordatus Wealth Management's 13F filing for Q1 2021, filed 26 Apr 2021.